Kingdon Capital Management, L.L.C. Otonomy, Inc. Call Options Transaction History

Kingdon Capital Management, L.L.C.

2 transactions

Quarter	Operation	Price Per call	calls change	calls Held	SEC Form
Q4 2017 Feb 14, 2018	SELL	$2.8 - $5.55 $1.18 Million - $2.34 Million	-422,100 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$3.2 - $20.8 $1.35 Million - $8.78 Million	422,100	422,100 $1.37 Million

Ticker OTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,990,400
Description
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurot...

Get notified when there are updates to the investment portfolio of Kingdon Capital Management, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Kingdon Capital Management, L.L.C. with notifications on news.